Cost-Benefit Analysis of Riluzole for the Treatment of Amyotrophic Lateral Sclerosis
- 1 November 1997
- journal article
- Published by Springer Nature in PharmacoEconomics
- Vol. 12 (5) , 578-584
- https://doi.org/10.2165/00019053-199712050-00008
Abstract
We conducted a cost-benefit analysis of riluzole therapy in patients with amyotrophic lateral sclerosis (ALS; motor neuron disease; Lou Gehrig’s disease). The survival of patients with ALS increased...Keywords
This publication has 19 references indexed in Scilit:
- Riluzole and amyotrophic lateral sclerosisThe Lancet, 1996
- Dose-ranging study of riluzole in amyotrophic lateral sclerosisThe Lancet, 1996
- Neuroprotective effects of riluzole in ALS CSF toxicityNeuroReport, 1994
- Amyotrophic lateral sclerosis. Communication status and survival with ventilatory support.1993
- Amino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disordersBrain Research Reviews, 1993
- Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.Journal of Epidemiology and Community Health, 1993
- Onset, natural history and outcome in idiopathic adult motor neuron diseaseJournal of the Neurological Sciences, 1993
- Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.Journal of Epidemiology and Community Health, 1992
- Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on d[3H]aspartate release from cultured cerebellar granule cellsNeuroscience Letters, 1992
- Risk factors in amyotrophic lateral sclerosis.1991